Aaron Fletcher Biography and Net Worth



Dr. Fletcher founded and serves as CEO of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. Bios Research provides fundamental healthcare industry research focused in the biotech and med-tech sub-sectors and through this research Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a PhD in Biochemistry from Colorado State University, and serves as a professor at Dallas Baptist University where he teaches Biochemistry, Bioethics, and Cell Biology. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over 10 years.

How do I contact Aaron G.L. Fletcher?

The corporate mailing address for Dr. Fletcher and other Actuate Therapeutics executives is 1751 RIVER RUN, SUITE 400, FORT WORTH, TX, 76107. Actuate Therapeutics can also be reached via phone at (847) 986-4190 and via email at [email protected]. Learn More on Aaron G.L. Fletcher's contact information.

Has Aaron G.L. Fletcher been buying or selling shares of Actuate Therapeutics?

Aaron G.L. Fletcher has not been actively trading shares of Actuate Therapeutics over the course of the past ninety days. Learn More on Aaron G.L. Fletcher's trading history.

Who are Actuate Therapeutics' active insiders?

Actuate Therapeutics' insider roster includes Aaron Fletcher (Director), and Todd Thomson (Director). Learn More on Actuate Therapeutics' active insiders.

Are insiders buying or selling shares of Actuate Therapeutics?

In the last twelve months, Actuate Therapeutics insiders bought shares 1 times. They purchased a total of 140,844 shares worth more than $49,295.40. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 280,000 shares worth more than $1,624,000.00. The most recent insider tranaction occured on October, 28th when CEO Daniel M Schmitt bought 140,844 shares worth more than $49,295.40. Insiders at Actuate Therapeutics own 58.0% of the company. Learn More about insider trades at Actuate Therapeutics.

Information on this page was last updated on 10/28/2026.

Aaron G.L. Fletcher Insider Trading History at Actuate Therapeutics

See Full Table

Aaron G.L. Fletcher Buying and Selling Activity at Actuate Therapeutics

This chart shows Aaron G.L. Fletcher's buying and selling at Actuate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Actuate Therapeutics Company Overview

Actuate Therapeutics logo
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Read More

Today's Range

Now: $0.29
Low: $0.28
High: $0.33

50 Day Range

MA: $0.67
Low: $0.29
High: $1.48

2 Week Range

Now: $0.29
Low: $0.28
High: $7.90

Volume

174,169 shs

Average Volume

451,342 shs

Market Capitalization

$6.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54